Drug intelligence / Profile preview

anagrelide-sar003

Development stage: Preclinical
Lead developer: Sartar Therapeutics
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Subcutaneous

Overview

SAR003 (anagrelide-sar003) is a novel small molecule drug candidate developed by Sartar Therapeutics. It acts as a phosphodiesterase 3 (PDE3) inhibitor and is being investigated for its potential as both monotherapy and in combination therapy for advanced gastrointestinal stromal tumors (GIST) and soft tissue sarcoma. The drug features a molecular glue mechanism of action and is formulated for superior subcutaneous long-acting delivery. As of the latest updates, it remains in preclinical development with the goal of providing curative therapy for advanced GIST and becoming frontline therapy in this indication[1][2].

Targets

SLFN12 (Schlafen family member 12)PDE3A (Phosphodiesterase 3A)

Beyond the preview

Go deeper on anagrelide-sar003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anagrelide-sar003.

Explore the full profile